麻豆社

Over 2700 people in England may be affected if health watchdog NICE decide not to approve a "breakthrough" treatment for people with cystic fibrosis for use on the NHS.

The drug Orkambi, which costs 拢104,000 a year per patient, has been shown to improve lung function and respiratory symptoms in people with cystic fibrosis, but NICE said the benefits were modest.

Fourteen-year-old Clara Mann, who has cystic fibrosis, and her father Nicholas Mann discuss the benefits the drug has had on her life.

(Image: Child with nurse. Credit: SPL)